Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Preoperative plasma cell-free DNA chromosomal instability predicts microvascular invasion in hepatocellular carcinoma: a prospective study

Fig. 2

ROC curve of MVI prediction with the UCAD and AFP models in different subgroups of HCC. (a) ROC of MVI prediction with the UCAD and AFP models in whole group patients (N = 74). (b) ROC of MVI prediction with the UCAD and AFP models in the subgroup of HCC patients with tumor size less than 3 cm (N = 42). (c) ROC of MVI prediction with the UCAD and AFP models for HCC patients with TACE treatment before liver surgery (N = 15). (d) ROC of MVI prediction with the UCAD and AFP models for HCC patients with recurrence (N = 18). (e) ROC of MVI prediction with the UCAD and AFP models for HCC patients at BCLC stage B and C (N = 10). (f) ROC of MVI prediction with the UCAD and AFP models in HCC patients with total tumor count ≥ 2 (N = 12). AFP, alpha fetoprotein; MVI, microvascular invasion. HCC, hepatocellular carcinoma; MVI, microvascular invasion; ROC, receiver operating characteristic; TACE, trans-arterial chemoembolization

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us